How should hospital procurement teams evaluate DTx vendors before signing enterprise contracts?

Prioritize vendors with at least two FDA-cleared or CE-marked products, documented EHR-integration APIs, and outcomes-based pricing options. Request published RCT data and payer-contracting references [12]. Read More

What liability exposure do prescribing physicians face when recommending a digital therapeutic?

Liability frameworks remain jurisdiction-specific, but FDA clearance shifts substantial product-liability risk to the manufacturer. Physicians should document prescribing rationale and monitor patient-reported outcomes [11]. Read More

How do DTx reimbursement rates compare with traditional cognitive-behavioral therapy sessions?

Reimbursement per episode typically ranges from USD 300 to USD 1,500, compared with USD 150–250 per in-person CBT session, though DTx rates bundle multi-week programs into a single payment [2]. Read More

What interoperability standards should health systems require from DTx platforms?

Require HL7 FHIR R4 compatibility, SMART on FHIR launch capability, and bidirectional data exchange with major EHR systems like Epic and Cerner [16]. Read More

How are DTx developers addressing patient attrition beyond the first 30 days?

Leading platforms deploy adaptive engagement engines that vary content difficulty, notification timing, and reward structures based on real-time usage patterns, lifting 90-day retention above 60% [5]. Read More

What role do companion diagnostics play in DTx personalization?

Companion biomarkers — such as continuous glucose readings or actigraphy sleep data — enable real-time algorithm adjustments that improve therapeutic precision and support outcomes-based payer contracts [10]. Read More

Can DTx platforms operate effectively in low-bandwidth environments below 3G connectivity?

Several platforms now offer offline-capable modules that sync data when connectivity resumes, enabling deployment in rural and low-infrastructure settings across Asia-Pacific and Africa [15]. Read More

Digital Therapeutics Market (2026 - 2035)

ID: MRFR/Pharma/5030-HCR

100 Pages

Rahul Gotadki

Last Updated: July 15, 2026

Digital Therapeutics Market Research Report By Application (Chronic Disease Management, Mental Health Disorders, Preventive Care, General Wellness), By Delivery Mode (Software, Device, Platform), By End User (Patients, Providers, Payers, Employers), By Therapeutic Area (Diabetes, Cardiology, Neurology, Oncology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Industry Forecast to 2035.

Digital Therapeutics Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)23.1%

2026 Market SizeUSD 13.22 Billion

2035 Market SizeUSD 85.80 Billion

Key Players

Omada Health

Teladoc Health

Noom

Click Therapeutics

Akili Interactive

Better Therapeutics

Trends

Regulatory Harmonization Accelerates Commercial Certainty
AI-Driven Personalization Lifts Engagement Metrics
Chronic-Disease Burden Expands the Addressable Patient Pool

Opportunities

Pharma Co-Prescription Bundling
Employer-Sponsored Behavioral Health Programs
Emerging-Market Leapfrog via Mobile-First Delivery

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Regulatory Harmonization (FDA, CMS, BfArM) | |
  2. 3.1.2 AI-Driven Personalization and Adaptive Algorithms | |
  3. 3.1.3 Rising Chronic-Disease Prevalence | |
  4. 3.1.4 Payer Reimbursement Expansion | |
  5. 3.1.5 Pharma–DTx Co-Development Partnerships | |
  6. 3.1.6 Mobile-Infrastructure Maturity in Emerging Markets | |
  7. 3.1.7 Employer-Sponsored Digital Wellness Mandates |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Fragmented Clinical-Evidence Standards Across Regulators | |
  2. 3.2.2 Low Clinician Awareness and Prescribing Inertia | |
  3. 3.2.3 Data-Privacy and Cybersecurity Concerns | |
  4. 3.2.4 Reimbursement Uncertainty in Emerging Markets | |
  5. 3.2.5 Patient Digital-Literacy Gaps and Device Access |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Pharma Co-Prescription Bundling | |
  2. 3.3.2 Employer-Sponsored Behavioral Health Programs | |
  3. 3.3.3 Emerging-Market Leapfrog via Mobile-First Delivery | |
  4. 3.3.4 Real-World Data Monetization and Outcomes-Based Contracts | |
  5. 3.3.5 Pediatric and Adolescent Therapeutic Expansion |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Digital Therapeutics Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Product Type | |
  1. 5.1.1 Software-Only Digital Therapeutics | |
  2. 5.1.2 Connected Devices | |
  3. 5.1.3 Virtual Reality & Gaming Solutions |
2. 5.2 By Therapeutic Area | |
  1. 5.2.1 Treatment (Diabetes, Substance-Use Disorder, Insomnia, and More) | |
  2. 5.2.2 Preventive (Pre-Diabetes, Behavioral Risk Factors, and More) |
3. 5.3 By Modality | |
  1. 5.3.1 Standalone Prescription DTx | |
  2. 5.3.2 DTx + Drug Combination | |
  3. 5.3.3 Over-the-Counter / Wellness |
4. 5.4 By End User | |
  1. 5.4.1 Direct-to-Consumer (Patients) | |
  2. 5.4.2 Providers / Hospitals | |
  3. 5.4.3 Payers / Insurers
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Omada Health | |
  2. 7.3.2 Teladoc Health (Livongo) | |
  3. 7.3.3 Noom | |
  4. 7.3.4 Click Therapeutics | |
  5. 7.3.5 Akili Interactive | |
  6. 7.3.6 Better Therapeutics | |
  7. 7.3.7 Virta Health | |
  8. 7.3.8 Voluntis | |
  9. 7.3.9 WellDoc | |
  10. 7.3.10 Happify Health (Twill)
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Powered Autonomous Care Loops |
2. 8.2 Platform Economics and Therapeutic Marketplaces |
3. 8.3 Decentralized Clinical Trials and Continuous Evidence Generation |
4. 8.4 ESG, Health Equity, and Value-Based Care Alignment
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Digital Therapeutics Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Digital Therapeutics Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis – Digital Therapeutics Market |
TABLE 4 Restraint Impact Analysis – Digital Therapeutics Market |
TABLE 5 Regional Market Share Summary – Digital Therapeutics Market, 2025 |
TABLE 6 North America Digital Therapeutics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 7 Europe Digital Therapeutics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 8 Asia-Pacific Digital Therapeutics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 South America Digital Therapeutics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Middle East & Africa Digital Therapeutics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Global Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 12 Global Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 13 Global Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 14 Global Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 15 Competitive Benchmarking Matrix – Global Digital Therapeutics Market, 2025 |
TABLE 16 Company Profiles – Key Players, Global Digital Therapeutics Market |
TABLE 17 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 18 North America Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 19 North America Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 20 North America Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 21 North America Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 22 Europe Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 23 Europe Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 24 Europe Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 25 Europe Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 26 Asia-Pacific Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 27 Asia-Pacific Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 28 Asia-Pacific Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 29 Asia-Pacific Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 30 South America Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 31 South America Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 32 South America Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 33 South America Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 34 Middle East & Africa Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 35 Middle East & Africa Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 36 Middle East & Africa Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 37 Middle East & Africa Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 38 United States Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 39 United States Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 40 United States Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 41 United States Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 42 Germany Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 43 Germany Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 44 Germany Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 45 Germany Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 46 China Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 47 China Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 48 China Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 49 China Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 50 India Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 51 India Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 52 India Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 53 India Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 54 Japan Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 55 Japan Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 56 Japan Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 57 Japan Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 58 Brazil Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 59 Brazil Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 60 Brazil Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 61 Brazil Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 62 Saudi Arabia Digital Therapeutics Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 63 Saudi Arabia Digital Therapeutics Market Size, by Therapeutic Area, 2021–2035 (USD Billion) |
TABLE 64 Saudi Arabia Digital Therapeutics Market Size, by Modality, 2021–2035 (USD Billion) |
TABLE 65 Saudi Arabia Digital Therapeutics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 66 Report Scope & Methodology Summary
13 LIST OF FIGURES |
FIGURE 1 Digital Therapeutics Market Dynamics — Drivers, Restraints & Opportunities |
FIGURE 2 Value Chain Analysis — Digital Therapeutics Market |
FIGURE 3 Porter's Five Forces Analysis — Digital Therapeutics Market |
FIGURE 4 Global Digital Therapeutics Market Size Trend (USD Billion), 2021–2035 |
FIGURE 5 Digital Therapeutics Market Share, by Product Type, 2025 |
FIGURE 6 Digital Therapeutics Market Share, by Therapeutic Area, 2025 |
FIGURE 7 Digital Therapeutics Market Share, by Modality, 2025 |
FIGURE 8 Digital Therapeutics Market Share, by End User, 2025 |
FIGURE 9 Digital Therapeutics Market Share, by Region, 2025 |
FIGURE 10 North America Digital Therapeutics Market Share, by Country, 2025 |
FIGURE 11 Europe Digital Therapeutics Market Share, by Country, 2025 |
FIGURE 12 Asia-Pacific Digital Therapeutics Market Share, by Country, 2025 |
FIGURE 13 South America Digital Therapeutics Market Share, by Country, 2025 |
FIGURE 14 Middle East & Africa Digital Therapeutics Market Share, by Country, 2025 |
FIGURE 15 Competitive Landscape — Market Share Distribution, 2025 |
FIGURE 16 Competitive Benchmarking Radar Chart, 2025

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
Product Type	Software-Only Digital Therapeutics; Connected Devices; Virtual Reality & Gaming Solutions	Software-Only Digital Therapeutics	Virtual Reality & Gaming Solutions
Therapeutic Area	Treatment; Preventive	Treatment	Preventive
Modality	Standalone Prescription DTx; DTx + Drug Combination; Over-the-Counter / Wellness	Standalone Prescription DTx	DTx + Drug Combination
End User	Direct-to-Consumer (Patients); Providers / Hospitals; Payers / Insurers	Direct-to-Consumer (Patients)	Payers / Insurers
Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Product Type

Sub-Segment	Key Trend
Software-Only Digital Therapeutics	App-store distribution and rapid regulatory clearance drive dominant share
Connected Devices	Biometric-sensor integration enables continuous chronic-care monitoring
Virtual Reality & Gaming Solutions	Immersive pain-management and neurorehabilitation modules gain FDA clearance

Software-only platforms remain the backbone of the Digital Therapeutics Market owing to their minimal hardware dependencies and scalable deployment model. Virtual reality and gaming solutions, while nascent in share, are attracting significant clinical interest for pediatric ADHD, chronic pain, and stroke rehabilitation.

By Therapeutic Area

Sub-Segment	Key Trend
Treatment	Diabetes, substance-use disorder, and insomnia anchor the largest evidence base
Preventive	Pre-diabetes interception and employer wellness programs accelerate growth

Treatment applications maintain the largest revenue contribution, driven by established clinical pathways and payer willingness to reimburse measurable health outcomes. Preventive programs are expanding rapidly as employers and public-health agencies invest in early intervention.

By Modality

Sub-Segment	Key Trend
Standalone Prescription DTx	Independent regulatory approval and clear HTA pathways support market leadership
DTx + Drug Combination	Pharma co-development partnerships create differentiated combination labels
Over-the-Counter / Wellness	Low-friction consumer access via app stores sustains broad user bases

Standalone prescription solutions dominate due to regulatory clarity, while drug–digital combinations represent a strategic frontier for pharmaceutical companies seeking to extend brand differentiation beyond patent expiry.

By End User

Sub-Segment	Key Trend
Direct-to-Consumer (Patients)	Self-pay and employer-funded wellness drive the largest user base
Providers / Hospitals	EHR-integrated clinical workflows embed DTx into care delivery
Payers / Insurers	Reimbursement code expansion converts out-of-pocket spend to covered benefits

Direct-to-consumer channels lead in revenue share, but the payer segment is poised for the fastest growth as health plans systematically add digital therapeutics to their formularies.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”